Exclusive Summary

• - Off-patent worldwide; IV ganciclovir is a mature generic suited for rapid distribution and tender entry.
• - Strong, recurring hospital demand across transplant, hematology/oncology, ICU and neonatology, with tens of thousands of treated cases annually.
• - Listed on WHO Essential Medicines and recommended by major guidelines as first-line IV induction for severe or tissue-invasive CMV.
• - US and EU-27 registrations signal stringent quality/compliance, enabling cross-market access and procurement credibility.
• - Delivers 50–80% drug-cost savings versus originator/high-priced alternatives, materially reducing inpatient treatment costs.